Construction of siRNA of targeted silence EFNA2 gene and application of siRNA in preparation of medicine for inhibiting lung adenocarcinoma cell growth

By designing siRNA targeting the EFNA2 gene and using lipid materials to carry it, it successfully inhibits the growth of lung adenocarcinoma cells, solving the problem of low lung cancer treatment efficiency in the prior art, and achieving efficient apoptosis of lung adenocarcinoma cells.

CN118979038APending Publication Date: 2024-11-19DALIAN NATIONALITIES UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411166935.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art has low cure rates for lung cancer, especially because the early symptoms of lung cancer are not obvious and the rate of advanced recurrence and metastasis is high, and effective targeted EFNA2 gene therapy methods are lacking.

Method used

Four siRNA sequences targeting the silencing EFNA2 gene were designed and constructed, and siRNA was carried to inhibit siRNA using lipid materials such as N,N-bistetradecanoyloxyamide and dioleylphosphatidylethanolamine as carriers. Growth of lung adenocarcinoma cells.

Benefits of technology

By silencing the EFNA2 gene, the growth of lung adenocarcinoma cells was significantly inhibited. The silencing effect of the siRNA-856 sequence was better than other sequences, causing apoptosis rate of lung tumor cells of 28.6%, and the lipid vector was not cytotoxic.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005008139840000021
    Figure BDA0005008139840000021
  • Figure FDA0005008139820000011
    Figure FDA0005008139820000011
  • Figure HDA0005008139850000011
    Figure HDA0005008139850000011
Patent Text Reader

Abstract

The invention belongs to the technical field of lung cancer inhibition drugs, and discloses siRNA construction of a targeted silence EFNA2 gene and application of siRNA in preparation of drugs for inhibiting lung adenocarcinoma cell growth. Comprising four siRNAs of silent EFNA2 genes and application of the siRNAs in preparation of drugs for inhibiting lung adenocarcinoma cell growth, and particularly, siRNAs of silent EFNA2 are carried by using a lipid material as a carrier. According to the four siRNA sequences for silencing the EFNA2, the silence effect of the siRNA-856 sequence is better than that of siRNA-495, siRNA-547 and siRNA-725, and the lung tumor cell apoptosis rate is 28.6%. The lipid carrier composed of peptide lipids CDO and DOPE can efficiently deliver four sequences of EFNA2-siRNA, and has no cytotoxicity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of lung cancer inhibitory drugs, and specifically relates to the construction of siRNA targeting and silencing EFNA2 gene and the application thereof in preparing drugs for inhibiting the growth of lung adenocarcinoma cells. Background Art

[0002] Cancer is one of the main factors threatening human life and health. In 2020, there were approximately 19.3 million new cancer cases and 9.96 million deaths worldwide. Among them, the incidence of lung cancer was approximately 2.21 million, and the mortality rate was approximately 1.8 million, ranking first, far exceeding other cancers. In 2022, there were approximately 4.8247 million new cancer cases and approximately 2.5742 million deaths in my country, among which the incidence (approximately 22%) and mortality (approximately 28%) of lung cancer ranked first. According to histopathological classification, lung cancer is mainly divided into non-small cell lung cancer (approximately 85%) and small cell lung cancer (approximately 15%). The current means of treating lung cancer are mainly surgical treatment, chemotherapy, radiotherapy and targeted therapy. However, since the early symptoms of lung cancer are not obvious, it is not easy to be found, and the recurrence and metastasis rate of late-stage surgery is high, the cure rate of lung cancer by traditional treatments is not high. Gene silencing therapy is post-transcriptional gene silencing triggered by small interfering RNA (siRNA). siRNA can strongly inhibit gene expression and has high sequence specificity. Compared with traditional antisense nucleotides, the efficiency of siRNA gene silencing is as high as tens to thousands times.

[0003] EFNA2 is a gene that encodes the Ephrin-A2 protein and belongs to the Eph family. Ephrin-A2 is a cell surface molecule that plays an important role in the development of the nervous system and angiogenesis. It interacts with its receptor EphA and is involved in regulating cell migration, adhesion, and intercellular signaling. In lung adenocarcinoma, the EFNA2 gene is highly expressed and becomes an important tumor marker, participating in regulating the proliferation, invasion, and metastasis of tumor cells, and has an important impact on the development of tumors. Using gene silencing therapy to reduce the expression of the EFNA2 gene in tumor tissue will become a new technology for the treatment of lung adenocarcinoma. Currently, there is no research on tumor treatment targeting the EFNA2 gene. Summary of the invention

[0004] In order to overcome the shortcomings of the prior art, the present invention provides a siRNA construction for targeting and silencing the EFNA2 gene and its application in preparing a drug for inhibiting the growth of lung adenocarcinoma cells. The EFNA2 gene is highly expressed in lung adenocarcinoma and is involved in regulating the proliferation, invasion and metastasis of tumor cells. Four siRNA sequences that can silence the target gene are designed, and lipid materials are used to carry the siRNA that silences EFNA2. Human lung adenocarcinoma cells A549 and H1299 are used as models to inhibit the growth of tumor cells by silencing the expression of the EFNA2 gene.

[0005] The above object of the present invention is achieved through the following technical scheme: there are four siRNAs for silencing the EFNA2 gene, namely EFNA2-Homo-495, EFNA2-Homo-547, EFNA2-Homo-725, and EFNA2-Homo-856; wherein the forward sequence of EFNA2-Homo-495 is shown as SEQ ID No.1, and the reverse sequence is shown as SEQ ID No.2; the forward sequence of EFNA2-Homo-547 is shown as SEQ ID No.3, and the reverse sequence is shown as SEQ ID No.4; the forward sequence of EFNA2-Homo-725 is shown as SEQ ID No.5, and the reverse sequence is shown as SEQ ID No.6; the forward sequence of EFNA2-Homo-856 is shown as SEQ ID No.7, and the reverse sequence is shown as SEQ ID No.8.

[0006] Another object of the present invention is to provide a method for constructing the siRNA for protecting the above-mentioned EFNA2 gene silencing, specifically, selecting the nucleotide of the RNA polymerase gene on the L2 fragment of the EFNA2 segmented genome as a target, synthesizing two siRNAs with a length of 21 bp, and modifying the 5' and 3' ends. The 5' end is phosphate-substituted, the 3' end hydroxyl group remains unchanged, and the 3' end is composed of two nucleotide bases to form a protruding hanging end.

[0007] Another object of the present invention is to protect the use of the above siRNA for silencing the EFNA2 gene in the preparation of drugs for inhibiting the growth of lung adenocarcinoma cells.

[0008] Furthermore, the use of the siRNA that silences the EFNA2 gene in the preparation of a drug for inhibiting the growth of lung adenocarcinoma cells specifically utilizes a lipid material as a carrier to carry the siRNA that silences EFNA2.

[0009] Furthermore, the lipid material is N,N-di-tetradecanoyloxyamideethyl trimerized ornithineamide (labeled as CDO) and dioleoylphosphatidylethanolamine (DOPE), and the structure of CDO is:

[0010]

[0011] Furthermore, the method of using lipid materials as carriers to carry siRNA that silences EFNA2 is specifically as follows: lipid CDO and DOPE are mixed and dissolved in chloroform at a mass ratio of 1:1, the chloroform is blown dry under N2 to form a thin and uniform film, ultrapure water is added and ultrasonic oscillation is performed alternately to prepare the lipid carrier CDO-DOPE. DOPE is not added to the formula, and the lipid carrier CDO is prepared with lipid CDO alone. The lipid carrier and siRNA are compounded at a mass ratio of 3:1 for delivery.

[0012] Compared with the prior art, the present invention has the following beneficial effects: among the four siRNA sequences designed by the present invention for silencing EFNA2, the silencing effect of the siRNA-856 sequence is better than that of siRNA-495, siRNA-547 and siRNA-725, and the apoptosis rate of lung tumor cells is 28.6%. The lipid carrier composed of peptide lipids CDO and DOPE can efficiently deliver the four sequences of EFNA2-siRNA without cytotoxicity. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments.

[0014] Figure 1 Schematic diagram of the relative gene expression of EFNA2 in A549, H1299 and BEAS-2B cells;

[0015] Figure 2 Schematic diagram of the protein expression level (A) and gray value (B) of EFNA2 in A549, H1299 and BEAS-2B cells;

[0016] Figure 3 Schematic diagram of the cytotoxicity of lipid carriers to normal lung epithelial cells BEAS-2B (cultured 48 hours after transfection);

[0017] Figure 4 Schematic diagram of the relative expression of EFNA2 gene (A), protein expression (B) and relative protein expression (C) in H1299 cells 48 hours after transfection of lipid carrier and siRNA-495 complex;

[0018] Figure 5 Schematic diagram of the relative expression level (A) of EFNA2 gene, protein expression (B) and relative protein expression (C) in H1299 cells 48 hours after transfection of lipid carrier and siRNA-547 complex;

[0019] Figure 6Schematic diagram of the relative expression level (A) of EFNA2 gene, protein expression (B) and relative protein expression (C) in H1299 cells 48 hours after transfection of lipid carrier and siRNA-725 complex;

[0020] Figure 7 Schematic diagram of the relative expression level (A) of EFNA2 gene, protein expression (B) and relative protein expression (C) in H1299 cells 48 hours after transfection of lipid carrier and siRNA-856 complex;

[0021] Figure 8 Schematic diagram of cell apoptosis 48 hours after H1299 cells were transfected with lipid carrier and siRNA-856 complex. DETAILED DESCRIPTION

[0022] The present invention is described in detail below by specific examples, but the protection scope of the present invention is not limited. Unless otherwise specified, the experimental methods used in the present invention are all conventional methods, and the experimental equipment, materials, reagents, etc. used can be obtained from commercial channels.

[0023] Example 1

[0024] The specific method of silencing the EFNA2 gene is as follows: H1299 cells were inoculated in a 6-well cell culture plate, with 0.5×10 6 ~1×10 6 cells, and incubated the cells in a 37°C, 5% CO2 incubator to a cell density of about 80%-90%. 2.4μg siRNA was diluted to 200μL with serum-free medium, and 7.2μg lipid carrier was diluted to 200μL with serum-free medium. The diluted siRNA was mixed with the lipid carrier at a mass ratio of 1:3, and allowed to stand at room temperature for 20min, and then 400μL of the above complex was added to each well. The control group did not add siRNA complex, incubated in the incubator for 4h, the original culture medium was discarded, and 2mL of RPMI 1640 medium containing 10% serum and 1% double antibody was added again, and the cells were cultured for 48h, and total RNA and total protein were extracted respectively, and the expression of EFNA2 gene was detected by RT-qPCR experiment and Western Blot experiment respectively.

[0025] Compared with human lung epithelial cells BEAS-2B, the expression of EFNA2 gene in human lung adenocarcinoma cells H1299 and A549 was significantly increased, about 3-4 times that of BEAS-2B cells.

[0026] Compared with human lung epithelial cells BEAS-2B, the expression level of EphrinA2, the protein corresponding to the EFNA2 gene, was significantly increased in human lung adenocarcinoma cells H1299 and A549.

[0027] After lipid vectors were transfected into normal lung epithelial cells BEAS-2B, the cell survival rate was greater than 90% after 48 hours of culture, indicating that the three lipid vectors had no obvious toxicity to normal lung epithelial cells BEAS-2B.

[0028] The lipid carrier CDO14-DOPE carried siRNA-495 and transfected human lung adenocarcinoma cell H1299. After transfection for 4 hours and culture for 48 hours, the silencing efficiency of the EFNA2 gene in the cells was 58.1%. The silencing efficiency of the EFNA2 gene in the lipid carrier CDO14 group cells was 23.4%, and the silencing efficiency of the EFNA2 gene in the commercial transfection reagent DOTAP group cells was 51.4%.

[0029] The lipid carrier CDO14-DOPE carried the siRNA-547 sequence and transfected human lung adenocarcinoma cell H1299. After transfection for 4 hours and culture for 48 hours, the gene silencing efficiency of EFNA2 in the cells was 70.2%. The silencing efficiency of EFNA2 gene in the cells of the lipid carrier CDO14 group was 29.7%, and the silencing efficiency of EFNA2 gene in the cells of the commercial transfection reagent DOTAP group was 56%.

[0030] The lipid carrier CDO14-DOPE carried siRNA-725 and transfected human lung adenocarcinoma cell H1299. After transfection for 4 hours and culture for 48 hours, the silencing efficiency of the EFNA2 gene in the cells was 70%, the silencing efficiency of the EFNA2 gene in the lipid carrier CDO14 group cells was 31.8%, and the silencing efficiency of the EFNA2 gene in the commercial reagent DOTAP group cells was 62.2%. The silencing effect of the siRNA-725 sequence was equivalent to that of siRNA-547 and better than that of siRNA-495.

[0031] After H1299 cells were transfected with siRNA-856 delivered by the lipid carrier CDO14-DOPE for 48 hours, the EFNA2 gene silencing efficiency in the cells was 80.7%. After H1299 cells were transfected with siRNA-856 delivered by the commercial transfection reagent DOTAP for 48 hours, the EFNA2 gene silencing efficiency in the cells was 70%. After H1299 cells were transfected with siRNA-856 delivered by the lipid carrier CDO14 for 48 hours, the EFNA2 gene silencing efficiency in the cells was 33.8%.

[0032] The apoptosis rate of lung tumor cells induced by EFNA2-siRNA-856 delivered by the lipid carrier CDO14-DOPE was 28.6%, the apoptosis rate of lung tumor cells induced by EFNA2-siRNA-856 delivered by the commercial transfection reagent DOTAP was 24.13%, and the apoptosis rate of lung tumor cells induced by EFNA2-siRNA-856 delivered by the lipid carrier CDO14 group was 11.39%, which was consistent with the experimental results of RT-qPCR and Western Blot.

[0033] In summary, among the four designed siRNA sequences that silence EFNA2, the silencing effect of siRNA-856 sequence is better than that of siRNA-495, siRNA-547 and siRNA-725, and the apoptosis rate of lung tumor cells is 28.6%. The lipid carrier composed of peptide lipids CDO and DOPE can efficiently deliver the four sequences of EFNA2-siRNA without cytotoxicity.

[0034] The above-described embodiments are only preferred embodiments of the present invention, but not all feasible embodiments of the present invention. For those skilled in the art, any obvious changes made thereto without departing from the principles and spirit of the present invention should be considered to be included in the scope of protection of the claims of the present invention.

Claims

1. An siRNA for silencing the EFNA2 gene, characterized in that: There are four siRNAs, named EFNA2-Homo-495, EFNA2-Homo-547, EFNA2-Homo-725, and EFNA2-Homo-856; the forward sequence of EFNA2-Homo-495 is shown as SEQ ID No.1, and the reverse sequence is shown as SEQ ID No.2; the forward sequence of EFNA2-Homo-547 is shown as SEQ ID No.3, and the reverse sequence is shown as SEQ ID No.4; the forward sequence of EFNA2-Homo-725 is shown as SEQ ID No.5, and the reverse sequence is shown as SEQ ID No.6; the forward sequence of EFNA2-Homo-856 is shown as SEQ ID No.7, and the reverse sequence is shown as SEQ ID No.

8.

2. The method for constructing siRNA for silencing EFNA2 gene according to claim 1, characterized in that: The steps are: selecting the nucleotides of the RNA polymerase gene on the L2 fragment of the EFNA2 segmented genome as the target, synthesizing two siRNAs with a length of 21 bp, and modifying the 5' and 3' ends; wherein the 5' end is phosphate-substituted, the 3' end hydroxyl group remains unchanged, and the 3' end is composed of two nucleotide bases to form a protruding hanging end.

3. Use of the siRNA for silencing the EFNA2 gene as claimed in claim 1 in the preparation of a drug for inhibiting the growth of lung adenocarcinoma cells.

4. Use of the siRNA for silencing the EFNA2 gene according to claim 3 in the preparation of a drug for inhibiting the growth of lung adenocarcinoma cells, characterized in that: Specifically, lipid materials are used as carriers to carry siRNA that silences EFNA2.

5. Use of the siRNA for silencing the EFNA2 gene according to claim 4 in the preparation of a drug for inhibiting the growth of lung adenocarcinoma cells, characterized in that: The lipid materials are CDO and DOPE, and the structure of CDO is:

6. Use of the siRNA for silencing the EFNA2 gene according to claim 4 in the preparation of a drug for inhibiting the growth of lung adenocarcinoma cells, characterized in that: The method of using lipid materials as carriers to carry siRNA for silencing EFNA2 is specifically as follows: lipid CDO and DOPE are mixed and dissolved in chloroform at a mass ratio of 1:1, the chloroform is blown dry under N2 to form a thin and uniform film, ultrapure water is added and ultrasonic oscillation is performed alternately to prepare lipid carrier CDO-DOPE; DOPE is not added to the formula, and lipid carrier CDO is prepared using lipid CDO alone. The lipid carrier and siRNA are compounded at a mass ratio of 3:1 for delivery.